Cargando…

Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery

For the prolonged, controlled delivery of systemic drugs, we propose an implantable drug-delivery chip (DDC) embedded with pairs of a microchannel and drug-reservoir serving as a drug diffusion barrier and depot, respectively. We pursued a DDC for dual drugs: a main-purpose drug, diclofenac (DF), fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Han Bi, Hong, Jae Young, Kim, Cho Rim, Min, Chang Hee, Han, Jae Hoon, Kim, Min Ji, Kim, Se-Na, Lee, Cheol, Choy, Young Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843219/
https://www.ncbi.nlm.nih.gov/pubmed/35147052
http://dx.doi.org/10.1080/10717544.2022.2032873
_version_ 1784651208943730688
author Ji, Han Bi
Hong, Jae Young
Kim, Cho Rim
Min, Chang Hee
Han, Jae Hoon
Kim, Min Ji
Kim, Se-Na
Lee, Cheol
Choy, Young Bin
author_facet Ji, Han Bi
Hong, Jae Young
Kim, Cho Rim
Min, Chang Hee
Han, Jae Hoon
Kim, Min Ji
Kim, Se-Na
Lee, Cheol
Choy, Young Bin
author_sort Ji, Han Bi
collection PubMed
description For the prolonged, controlled delivery of systemic drugs, we propose an implantable drug-delivery chip (DDC) embedded with pairs of a microchannel and drug-reservoir serving as a drug diffusion barrier and depot, respectively. We pursued a DDC for dual drugs: a main-purpose drug, diclofenac (DF), for systemic exposure, and an antifibrotic drug, tranilast (TR), for local delivery. Thus, the problematic fibrotic tissue formation around the implanted device could be diminished, thereby less hindrance in systemic exposure of DF released from the DDC. First, we separately prepared DDCs for DF or TR delivery, and sought to find a proper microchannel length for a rapid onset and sustained pattern of drug release, as well as the required drug dose. Then, two distinct DDCs for DF and TR delivery, respectively, were assembled to produce a Dual_DDC for the concurrent delivery of DF and TR. When the Dual_DDC was implanted in living rats, the DF concentration in blood plasma did not drop significantly in the later periods after implantation relative to that in the early periods before fibrotic tissue formation. When the Dual_DDC was implanted without TR, there was a significant decrease in the blood plasma DF concentration as the time elapsed after implantation. Biopsied tissues around the Dual_DDC exhibited a significant decrease in the fibrotic capsule thickness and collagen density relative to the Dual_DDC without TR, owing to the effect of the local, sustained release of the TR.
format Online
Article
Text
id pubmed-8843219
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88432192022-02-15 Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery Ji, Han Bi Hong, Jae Young Kim, Cho Rim Min, Chang Hee Han, Jae Hoon Kim, Min Ji Kim, Se-Na Lee, Cheol Choy, Young Bin Drug Deliv Research Article For the prolonged, controlled delivery of systemic drugs, we propose an implantable drug-delivery chip (DDC) embedded with pairs of a microchannel and drug-reservoir serving as a drug diffusion barrier and depot, respectively. We pursued a DDC for dual drugs: a main-purpose drug, diclofenac (DF), for systemic exposure, and an antifibrotic drug, tranilast (TR), for local delivery. Thus, the problematic fibrotic tissue formation around the implanted device could be diminished, thereby less hindrance in systemic exposure of DF released from the DDC. First, we separately prepared DDCs for DF or TR delivery, and sought to find a proper microchannel length for a rapid onset and sustained pattern of drug release, as well as the required drug dose. Then, two distinct DDCs for DF and TR delivery, respectively, were assembled to produce a Dual_DDC for the concurrent delivery of DF and TR. When the Dual_DDC was implanted in living rats, the DF concentration in blood plasma did not drop significantly in the later periods after implantation relative to that in the early periods before fibrotic tissue formation. When the Dual_DDC was implanted without TR, there was a significant decrease in the blood plasma DF concentration as the time elapsed after implantation. Biopsied tissues around the Dual_DDC exhibited a significant decrease in the fibrotic capsule thickness and collagen density relative to the Dual_DDC without TR, owing to the effect of the local, sustained release of the TR. Taylor & Francis 2022-02-11 /pmc/articles/PMC8843219/ /pubmed/35147052 http://dx.doi.org/10.1080/10717544.2022.2032873 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ji, Han Bi
Hong, Jae Young
Kim, Cho Rim
Min, Chang Hee
Han, Jae Hoon
Kim, Min Ji
Kim, Se-Na
Lee, Cheol
Choy, Young Bin
Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title_full Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title_fullStr Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title_full_unstemmed Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title_short Microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
title_sort microchannel-embedded implantable device with fibrosis suppression for prolonged controlled drug delivery
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843219/
https://www.ncbi.nlm.nih.gov/pubmed/35147052
http://dx.doi.org/10.1080/10717544.2022.2032873
work_keys_str_mv AT jihanbi microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT hongjaeyoung microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT kimchorim microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT minchanghee microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT hanjaehoon microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT kimminji microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT kimsena microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT leecheol microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery
AT choyyoungbin microchannelembeddedimplantabledevicewithfibrosissuppressionforprolongedcontrolleddrugdelivery